logo
Trump to Launch Private Health Tracking System With Tech Firms

Trump to Launch Private Health Tracking System With Tech Firms

Time​ Magazine19 hours ago
The Trump Administration announced a new initiative on Wednesday designed to allow Americans to share their medical records across a host of apps and programs managed by private tech companies—a move that proponents says will facilitate easier access to those records across the country's fragmented health care system, but that digital privacy experts fear will risk making patients' data less secure.
'For decades, America's health care networks have been overdue for a high-tech upgrade and that's what we are doing,' President Donald Trump said during an event announcing the initiative on Wednesday afternoon.
The Administration 'secured commitments' from more than 60 tech and health care companies—including Amazon, Apple, Google, and OpenAI—'to begin laying the foundation for a next-generation digital health ecosystem that will improve patient outcomes, reduce provider burden, and drive value,' according to a press release from the U.S. Centers for Medicare & Medicaid Services (CMS).
Making health records more easily accessible has been a goal of the federal government for decades, with the hope of allowing patients to seamlessly switch between providers. But such efforts have long been dogged by concerns over privacy and the challenges of companies offering competing proprietary records systems.
The Administration's new initiative, according to CMS, will focus on 'easily and seamlessly' sharing information between patients and medical providers, as well as 'increasing the availability of personalized tools so that patients have the information and resources they need to make better health decisions.' Initial goals of the initiative include apps that focus on diabetes and obesity management, using conversational AI assistants to help patients, and replacing paper intake forms with digital check-in options.
The announcement was the latest move by the Trump Administration to emphasize the value of incorporating the latest technology in the health system. In June, Health and Human Services Secretary Robert F. Kennedy Jr. testified in a congressional hearing about how he sees 'wearables' like smart watches as a game changer in health care.
'We think that wearables are a key to the MAHA agenda—Making America Healthy Again. My vision is that every American is wearing a wearable within four years,' Kennedy said.
The announcement prompted immediate pushback from digital privacy experts, who warned of the dangers of sharing health data with companies that aren't covered by the Health Insurance Portability and Accountability Act, or HIPAA, the federal law that protects personal health information from being shared by certain entities, such as medical providers and insurers, without a person's consent.
Andrew Crawford, a senior policy counsel at the Center for Democracy and Technology, says he has concerns about how the data will be collected and used by the companies involved in the initiative, what consumers will be told about their data privacy, and what limits there will be on how the data can be used and shared. If the company were to share a patient's information that went beyond the requested health service—like with advertisers that could then potentially target that individual based on inferences from their health data—that would be problematic, Crawford says.
Another unanswered question, he says, is in what circumstances, if any, the government would be able to access patients' health data through this initiative, and, if so, how they may or may not use that information.
'We've seen recently this Administration creating data sets that didn't exist before and using them for things like immigration enforcement,' Crawford says. He points to reproductive health choices as an example of medical data that many would be uncomfortable being shared across so many companies. Many apps also collect location data, Crawford notes, so he worries about the possibility that the data collected could show, for instance, if people traveled out of state to access abortion care that isn't legal in their home state.
CMS said in its announcement that the initiative will be 'more secure, and more personalized,' and 'use secure digital identity credentials to obtain medical records from CMS Aligned Networks.'
Dr. Brian Anderson, chief executive officer of the Coalition for Health AI, a nonprofit focused on creating guidelines for the responsible use of AI in health care, agrees there are 'some outstanding questions' about the initiative, including what protections will be in place to ensure that the data shared with tech companies not covered by HIPAA will remain private. But he believes this is a challenge that can be addressed.
'We just need to come together, as both private sector and public sector, and clearly define what those rules of the road are to ensure that patients' data is used in ways only that they intend and want it to be used,' Anderson says.
He says that he is 'very excited' to see a group of tech companies pledging to 'to make it easier for patients to have access to their own data,' especially since 'our data is oftentimes not in one centralized place.'
Still, others were unsure that this initiative would produce much benefit for patients, particularly if their sensitive medical records end up compromised.
'I think our system is designed to promote sharing already,' Crawford says. 'There are issues and there are hang-ups and flaws in that system, but I'm not sure—because I haven't seen the details yet—on if and how this announcement that's sharing more information with private entities, many of which may be outside HIPAA, will do anything to increase the quality of care.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Top-Rated Professional Medical Billing Services in USA
Top-Rated Professional Medical Billing Services in USA

Time Business News

time27 minutes ago

  • Time Business News

Top-Rated Professional Medical Billing Services in USA

A key component of the healthcare revenue cycle is medical billing. Accuracy, quickness, and adherence to the most recent regulations are guaranteed by Professional Medical Billing Services in USA. Billing firms with headquarters in the US offer customized services to clinics, hospitals, and private practices. Time and money are saved through outsourcing. While billing professionals take care of the paperwork, providers can concentrate on patient care. Expert services boost income and decrease denials. They make use of sophisticated billing software and certified programmers. Coding and billing errors are decreased by experts. Claims that are accurate result in fewer denials and quicker payouts. To protect patient data, these services adhere to industry standards and HIPAA requirements. Filing a claim on time is crucial. For providers, delays might cost thousands of dollars. Clean claims are promptly submitted by U.S. billing services to save needless back and forth with insurance. Every practice is unique. Flexible plans are provided by billing providers to accommodate particular requirements. There is a solution for both major hospitals and lone practitioners. Numerous services concentrate on particular specialties, such as pediatrics, dermatology, or cardiology. This guarantees that they are aware of the necessary codes, modifiers, and invoicing intricacies. Revenue Cycle Management (RCM): Leading businesses offer comprehensive RCM assistance. They take care of everything, from patient registration to ultimate reimbursement. Through frequent reporting, they evaluate patterns and maximize collections. Selecting the appropriate partner is essential. Keep an eye out for these essential characteristics: • Certified Coders: Professionals with AAPC or AHIMA certifications.• Real-time reporting: dashboards that are current and transparent.• Verification of insurance: Prompt inspections save problems later.• Denial Management: Resolving rejected claims as soon as possible. • Patient Billing Services: Professional, lucid patient communications. A number of U.S.-based billing companies are notable for their excellence and output: Athenahealth offers comprehensive services with robust analytics. Their platform is perfect for hospitals and big gatherings. Profits are harm by mistakes and delays. Faster payouts and fewer reject claims are guaranteed by a skill billing staff. Correct coding raises the percentage of reimbursements. Workflow is enhance and administrative stress is decreased by automated systems. In the USA, medical billing businesses adhere to stringent HIPAA regulations. They employ secure servers, encrypted platforms, and frequent employee training. The constant protection of patient data fosters compliance and fosters confidence. Cost is determined by the number of claims, practice size, and services need. A percentage of collections, often ranging from 4% to 9%, is what most suppliers charge. Transparent pricing structures are indicative of a reliable business. Prior to recruiting, inquire about the following: • Do they possess prior experience in your field of expertise?• How often do they accept claims on average?• Are they able to offer customer references?• How do they respond when a claim is denied? • Is it simple to utilize their software? In the USA, expert medical billing services increase productivity and revenue. They expedite payments, lower claim errors, and free up healthcare personnel to concentrate on patient care. Selecting the appropriate billing partner is crucial. Kareo is an expert in billing for small practices. They provide support services and cloud-based applications. TIME BUSINESS NEWS

The Man Who Was Too MAHA for the Trump Administration
The Man Who Was Too MAHA for the Trump Administration

Atlantic

time27 minutes ago

  • Atlantic

The Man Who Was Too MAHA for the Trump Administration

Vinay Prasad, until Tuesday one of the country's top medical regulators, just got a bitter taste of what it means to have real power. In recent months, the academic hematologist-oncologist, medical contrarian, and polemic podcaster had become a central figure at the U.S. Food and Drug Administration. In May, he was chosen to lead its Center for Biologics Evaluation and Research—a position that gave him authority over vaccines and gene therapies. In June, Marty Makary, who is currently the FDA commissioner, bestowed upon him an even more important role: chief medical and scientific officer of the entire agency. This week, Prasad abruptly departed. We don't know the exact reason behind Prasad's departure. According to a Department of Health and Human Services spokesperson, he resigned to 'spend more time with his family.' (Neither Prasad nor HHS responded to my request for comment.) Politico reports that President Donald Trump ordered his removal this week over the objections of Makary and Health and Human Services Secretary Robert F. Kennedy Jr. Whatever the particulars, Prasad's sudden need for a better work-life balance suggests the administration is following a time-honored approach to medical regulation: Business comes first. Prasad's troubles began in the first weeks of his tenure at the FDA, when he overruled the agency's own scientific reviewers by limiting the use of COVID vaccines. In doing so, he managed to anger the country's pro- and anti-vaccine factions at the same time. While many public-health experts criticized the decision to limit access to the shots, Kennedy's allies in the 'Make America healthy again' movement felt betrayed by the fact that the government had allowed mRNA shots to remain available at all. Prasad also faced a blitz from the pharmaceutical industry and patient-advocacy groups after the FDA tried to suspend distribution of a gene therapy for Duchenne muscular dystrophy called Elevidys, over safety concerns. For those affected by this rare, incurable condition, the move was seen as an outrageous denial of their right to weigh the drug's risks and benefits for themselves, and an extinguishing of what had been at least a glimmer of hope. Two days later, the right-wing provocateur Laura Loomer publicly accused Prasad of 'sabotaging Trump's deregulatory agenda,' and an opinion writer for The Wall Street Journal declared him a 'one-man death panel.' I know Prasad a bit: I've twice been a guest on his podcast, and I've followed his prolific academic work and public commentary about evidence-based medicine since about 2016, when he was a young professor at Oregon Health & Science University working to identify low-value medical practices. We've had our disagreements over the years. But with respect to Elevidys and drugs like it, our views are in alignment. We share the worry, for example, that the FDA keeps lowering its approval standards for drugs that keep getting more expensive. 'The American economy can handle a great deal of wasteful health-care spending,' Prasad told me in an interview in 2021. 'But it can't tolerate an infinite number.' His skepticism of Elevidys, in particular, is both long-standing and well-founded. The therapy has not been conclusively shown to slow the progression of the muscle-wasting disease it targets, but it does often induce vomiting and damage patients' livers. Worryingly, it also appears to be related to a pair of deaths. Prasad's predecessor in his role at CBER, Peter Marks, approved the drug, which costs $3.2 million per course of treatment, in spite of his own staff's uncertainty about its benefit. (Marks was forced out by Kennedy this spring, after the two clashed over access to vaccine-safety data.) Read: The sanewashing of RFK, Jr. That Prasad should take a tough line on drug regulation was perfectly in keeping with his history. He rose to prominence on that basis: To his many fans, he was a dogged and courageous industry watchdog; to his many critics, a self-righteous pharma scold. That mainstream Republicans should balk at this approach, and strive to undo it, was equally predictable. Politicians, particularly those on the right, have for years supported patients' ability to obtain still-unproven therapies. During Trump's first term, the president signed into law the 'Right to Try Act,' which expanded access to experimental drugs. That law was championed by Republican Senator Ron Johnson, who, according to reporting from STAT, may have been instrumental in Prasad's ouster. One might have guessed that things were different now in Washington—that Kennedy's eccentric philosophy had ushered in a novel form of conservative leadership, in which business interests didn't always lead the way. Thus far, however, the MAHA movement has done little to adjust the status quo. Instead, it has mostly wallowed in its own contradictions. We've been told that cooking with seed oils is toxic but that treating measles with cod-liver oil is great; and that both deworming pills and microbe-laden raw milk are good for you. MAHA leaders have declared the FDA a ' sock puppet of industry ' from which Prasad himself would provide a ' welcome reprieve,' while also championing the public's right to choose its food and drugs (even as they interfere with the distribution of some vaccines). So which is it? Should people have easy access to almost any health-care intervention, or should the government protect vulnerable patients from drugs for which there isn't rigorous evidence of benefit? For years, Prasad has been clear on where he stands in that regard. 'It is not a case of patients who crave risk facing off with regulators who abhor it,' he wrote in a medical journal in 2019. Rather, the current system, in which 'reliable data are inconsistently generated,' has failed patients who wish to make informed decisions about their care. Whenever this tension has been tested in the Trump administration, MAHA leaders have almost always seemed inclined to move the other way. A recent op-ed by the FDA's Makary and Mehmet Oz, the head of the Centers for Medicare & Medicaid Services, summed up the current regulatory approach as follows: Agency bureaucrats should cooperate with industry leaders instead of antagonizing them, and the government should favor 'market solutions' over 'prescriptive regulation.' Indeed, even as the news of Prasad's firing was coming out, Makary was promoting his 'national listening tour' of private interests. 'Looking forward to hearing from more pharma and biotech CEOs!' he wrote on X. Prasad himself appeared to recognize which way the wind was blowing. From the moment he took office, he was tempering his point of view. Before he became a political appointee, Prasad was dogmatic in his dismissal of evidence that did not emerge from large, randomized clinical trials. ('As readers know, my philosophy is RCT or STFU,' he wrote in his newsletter in 2023.) But Prasad seemed to back away from this idea even in his opening remarks to his new colleagues and staffers. 'Randomized controlled trials are not always necessary, and when they are done, they are not always informative,' he reportedly said on May 7, his second day on the job. Such appeasement efforts proved insufficient to protect him from rival forces in the Republican Party, if not also in the MAHA movement itself. For the moment, Prasad has been replaced at CBER by the wealthy biomedical entrepreneur George Tidmarsh. Surely that will come as a relief to a constituency that seems to hold immense sway with this administration: America's drug companies and medical-device makers.

AI May Replace $100K Jobs But Create Even More Opportunities
AI May Replace $100K Jobs But Create Even More Opportunities

Yahoo

time29 minutes ago

  • Yahoo

AI May Replace $100K Jobs But Create Even More Opportunities

Credit - Photo-Illustration by Chloe Dowling (Source Images: Yevgen Romanenko—Getty Images, Vithun Khamsong—Getty Images, Andriy Onufriyenko—Getty Images, ViewStock/Getty Images, Rawpixel/Getty Images) We are entering a new industrial revolution, powered not by steam or steel, but by artificial intelligence. The shift is rapid, relentless, and, for millions of Americans, deeply uncertain. AI is now automating white-collar jobs once considered untouchable: legal research, accounting, medical diagnostics, coding, and marketing. The $100,000 salary that once guaranteed security is, in many cases, being performed faster and cheaper by an algorithm. But if we act now with intention, compassion, and strategy, this technological disruption could become the greatest opportunity of our generation. We could use AI to create millions of new, dignified, middle-class jobs, empower the overlooked and underestimated, and, perhaps for the first time in a long time, rebuild the American Dream from the bottom up. AI will undoubtedly increase efficiency. But productivity is only half the equation. Roughly 70% of U.S. GDP comes from consumer spending. That means we need people with paychecks and purpose to keep the economy growing. Displacing 30% of workers without a plan doesn't grow the economy. It risks shrinking it. More profit, fewer customers. More automation, less inclusion. That's a dangerous imbalance. Read More: 'The Dead Have Never Been This Talkative': The Rise of AI Resurrection This summer, in partnership with Georgia State University, Operation Hope launched the AI Literacy Pipeline to Prosperity Project (AILP3). Fifty young people from Atlanta were trained in AI tools and use cases. More importantly, they were taught to believe that this future includes them. Imagine scaling that model across every city and rural town in America. The most exciting truth of the AI era is this: many of tomorrow's best-paying jobs won't require a four-year degree. They'll require skills, curiosity, digital fluency, and the ability to work with smart tools. We need AI-assisted logistics operators, financial coaches using smart tools, and health aides empowered by AI diagnostics. These jobs can ultimately pay more than $100K, but only if we build the pipelines to reach them. Access and education remain the barriers. We can break those down with public-private partnerships, community-based training, and AI literacy embedded into workforce programs. Inclusion is often framed as the right thing to do. It is. It's also the smart thing to do. If we empower just 30% more Americans, especially from underserved communities, to fully participate in the AI economy, we could unlock 2–3% additional annual GDP growth. That's not ideology. It's economic strategy. Read More: AI Can't Replace Education—Unless We Let It We must tie Community Reinvestment Act funding to AI education and access, incentivize companies to hire re-skilled workers from diverse backgrounds, back AI-for-good startups led by underrepresented founders, and make digital skills the new infrastructure—as essential as bridges and broadband. Let's stop talking about AI as if it's a threat to humanity. The real threat is leaving humans out of the opportunity it creates. We don't need another elite tech boom. We need a broad-based economic revival, one that restores dignity, grows wages, and expands ownership from the ground up. The American Dream isn't dead, but it does need a reboot. AI, used wisely and inclusively, can be the code that helps us run it again—this time, better than before. Contact us at letters@

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store